Molecular Partners Ag (MOLN) Interest Coverage Ratio (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Interest Coverage Ratio of 1195.91 for Q1 2026, up 7461.27% year-over-year from 15.82 in Q1 2025, and up 10098.95% quarter-over-quarter from 11.96 in Q4 2025.
Molecular Partners Ag (MOLN) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Interest Coverage Ratio for 7 consecutive years, with 1195.91 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 7461.27% year-over-year to 1195.91; the TTM figure through Mar 2026 stood at 9.15 (up 99.32% YoY), while the FY2025 annual figure was 11.52, up 99.29% from the prior year.
- Interest Coverage Ratio rose to 1195.91 in Q1 2026 per MOLN's latest filing, from 11.96 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1195.91 in Q1 2026 and bottomed at 1431.99 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 158.32 across 5 years, with a median of 27.53 in 2023.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio sank 12459.08% — and 2026, when it soared 7461.27%.
- Molecular Partners Ag's Interest Coverage Ratio stood at 191.28 in 2022, then slumped by 105.96% to 11.4 in 2023, then tumbled by 12459.08% to 1431.99 in 2024, then soared by 99.16% to 11.96 in 2025, then soared by 10098.95% to 1195.91 in 2026.
- Business Quant data shows MOLN's Interest Coverage Ratio at 1195.91 in Q1 2026, 11.96 in Q4 2025, and 76.39 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 1.42 |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | 1,222.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,195.91 |
| Dec 31, 2025 | -11.96 |
| Sep 30, 2025 | 76.39 |
| Jun 30, 2025 | -4.95 |
| Mar 31, 2025 | 15.82 |
| Dec 31, 2024 | -1,431.99 |
| Sep 30, 2024 | 7.48 |
| Jun 30, 2024 | -887.56 |
| Mar 31, 2024 | 1,133.50 |
| Dec 31, 2023 | -11.40 |
| Sep 30, 2023 | 1,040.91 |
| Jun 30, 2023 | -13.32 |
| Mar 31, 2023 | 27.53 |
| Dec 31, 2022 | 191.28 |
| Sep 30, 2022 | 114.86 |
| Jun 30, 2022 | 633.00 |
| Mar 31, 2022 | 615.97 |
| Dec 31, 2021 | -108.23 |
| Sep 30, 2021 | 94.96 |
| Jun 30, 2021 | 106.12 |